Leading Product Revenue

February 7, 2025

(¥ million)

Brand name	Active ingredient	Indications	Launch date	Sales FY2022 (IFRS)	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)
Brand name	Active ingredient	Indications	Launch date	Sales FY2022 (IFRS)	Sales FY2023 (IFRS)	Apr-Dec	Full-year (estimated)
Viltepso				14,341	17,530	16,389	21,850
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,139)	(4,407)	(3,527)	(4,600)
(U.S.)				(10,201)	(13,123)	(12,861)	(17,250)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	10,543	12,918	11,623	15,200
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	15,951	10,383	4,111	5,100
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukimia	Aug-2018/ Dec-2022	4,904	4,695	3,805	4,900
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	-	3,737	4,900
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	5,358	3,927	2,179	2,700
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,524	2,221	2,090	2,400
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,938	2,499	1,932	2,400
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	2,649	2,255	1,302	1,600
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	2,826	2,256	1,235	1,600
Erizas	dexamethasone cipecilate	allergic rhinitis	Dec-2009	2,640	2,284	916	2,000
Profit in co-promotion				9,520	8,658	7,132	9,100
Revenues from the licensing of industrial property rights				30,714	40,304	34,071	45,650
Pharmaceuticals				121,988	125,105	104,560	138,500
Functional Food				22,187	23,150	16,759	21,500
Revenue				144,175	148,255	121,320	160,000

Brand name	Active ingredient	Indications	Launch date	Sales FY2022 (IFRS)	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)
Brand name	Active ingredient	Indications	Launch date	Sales FY2022 (IFRS)	Sales FY2023 (IFRS)	Apr-Dec	Full-year (estimated)
Viltepso				14,341	17,530	16,389	21,850
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,139)	(4,407)	(3,527)	(4,600)
(U.S.)				(10,201)	(13,123)	(12,861)	(17,250)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	10,543	12,918	11,623	15,200
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	15,951	10,383	4,111	5,100
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukimia	Aug-2018/ Dec-2022	4,904	4,695	3,805	4,900
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	-	3,737	4,900
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	5,358	3,927	2,179	2,700
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,524	2,221	2,090	2,400
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,938	2,499	1,932	2,400
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	2,649	2,255	1,302	1,600
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	2,826	2,256	1,235	1,600
Erizas	dexamethasone cipecilate	allergic rhinitis	Dec-2009	2,640	2,284	916	2,000
Profit in co-promotion				9,520	8,658	7,132	9,100
Revenues from the licensing of industrial property rights				30,714	40,304	34,071	45,650
Pharmaceuticals				121,988	125,105	104,560	138,500
Functional Food				22,187	23,150	16,759	21,500
Revenue				144,175	148,255	121,320	160,000

Back Number

Related Link

Nippon Shinyaku’s DNA

Research & Development

Business/Financial Information